Lundbeck Shifts Focus to U.S. and China Amid European Drug Pricing Pressures

Danish pharmaceutical giant H. Lundbeck A/S is redirecting its investment strategy toward the U.S. and China as returns from drug sales in Europe weaken. The move underscores growing challenges in regulated markets with constrained pricing.

• Lundbeck is prioritizing investment in the U.S. and China over Europe
• Drug revenue returns are lagging in Europe due to pricing pressures
• The shift reflects challenges in regulated markets with constrained reimbursement
• Global pharma investment flows may realign toward higher R&D return regions
• Sector ETFs XLV and SPY may reflect changing market sentiment
• Pfizer (PFE) could be indirectly impacted by shifting capital allocation